As of October 2025, the U.S. stock market has been experiencing significant volatility, with major indices like the Nasdaq and S&P 500 rebounding sharply after recent declines due to geopolitical tensions. This dynamic environment underscores the importance of identifying high-growth tech stocks that can capitalize on evolving market conditions, particularly those demonstrating resilience and innovation in response to global economic shifts.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| ADMA Biologics | 20.60% | 23.25% | ★★★★★☆ |
| Palantir Technologies | 25.11% | 31.65% | ★★★★★★ |
| RenovoRx | 65.52% | 68.63% | ★★★★★☆ |
| Workday | 11.20% | 32.07% | ★★★★★☆ |
| Aldeyra Therapeutics | 42.92% | 73.80% | ★★★★★☆ |
| OS Therapies | 56.64% | 68.61% | ★★★★★☆ |
| Vanda Pharmaceuticals | 22.66% | 59.11% | ★★★★★☆ |
| Circle Internet Group | 27.84% | 82.07% | ★★★★★☆ |
| Zscaler | 15.74% | 40.36% | ★★★★★☆ |
| Gorilla Technology Group | 32.75% | 122.61% | ★★★★★☆ |
Click here to see the full list of 71 stocks from our US High Growth Tech and AI Stocks screener.
Let's dive into some prime choices out of from the screener.
Gyre Therapeutics (GYRE)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $722.98 million.
Operations: Gyre Therapeutics focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, generating revenue primarily from its Gyre Pharmaceuticals segment, which reported $102.19 million.
Gyre Therapeutics has recently been spotlighted for its robust growth metrics and strategic executive movements, underscoring its potential in the high-growth biotech sector. With an impressive annual revenue increase forecast at 24.6% and earnings expected to surge by 53.2%, Gyre is outpacing both its industry and broader market expectations. The company's commitment to innovation is evident from its R&D spending trends, which have strategically aligned with key product launches poised to drive future revenues. Moreover, the addition of Dr. Dan Weng to the board and strategic executive shifts signal a reinforced focus on expanding their research capabilities and market reach, potentially catalyzing further growth in a competitive landscape.
Protagonist Therapeutics (PTGX)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide therapeutics for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases, with a market cap of $5.41 billion.
Operations: Protagonist Therapeutics generates revenue primarily from its biotechnology segment, specifically focused on startups, amounting to $209.18 million. The company operates within the biopharmaceutical sector, targeting hematology and blood disorders along with inflammatory and immunomodulatory diseases.
Amidst swirling M&A rumors with Johnson & Johnson, Protagonist Therapeutics stands out for its strategic partnerships and innovative pipeline in immune disease treatments. With a projected annual revenue growth of 22.5% and earnings growth at 37.9%, the company is positioned above many peers in the biotech sector. Despite recent financial setbacks, including a significant net loss reported for the first half of 2025, Protagonist's R&D commitment remains robust, aligning closely with its forward-looking strategies in oral treatment developments for diseases like plaque psoriasis and ulcerative colitis. This focus on specialized therapies could potentially enhance its market presence post-acquisition discussions, reflecting not just recovery but an opportunity for substantial growth leveraging J&J's commercial capabilities.
- Get an in-depth perspective on Protagonist Therapeutics' performance by reading our health report here.
Understand Protagonist Therapeutics' track record by examining our Past report.
Daktronics (DAKT)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Daktronics, Inc. is a company that specializes in designing, manufacturing, and selling electronic scoreboards and display systems for various applications including sports, commercial, and transportation sectors globally, with a market cap of approximately $929.84 million.
Operations: The company's revenue streams are primarily derived from Commercial ($168.17 million), Live Events ($262.68 million), and High School Park and Recreation ($177.26 million) segments. It also generates revenue from International ($66.11 million) and Transportation ($75.15 million) sectors, reflecting a diverse market presence in electronic display solutions across different industries.
Daktronics has demonstrated resilience and adaptability in the high-tech industry, evidenced by a significant turnaround in its financial performance. For Q1 2026, the company reported a net income of $16.47 million, rebounding from a net loss of $4.95 million in the previous year, highlighting its capability to recover and stabilize financially. This improvement is backed by strategic share repurchases amounting to $53.97 million since 2016, reinforcing shareholder value amidst market fluctuations. Additionally, Daktronics' commitment to innovation is underscored by an R&D expense ratio that aligns with industry standards for fostering growth and maintaining competitiveness in evolving tech landscapes.
- Navigate through the intricacies of Daktronics with our comprehensive health report here.
Assess Daktronics' past performance with our detailed historical performance reports.
Turning Ideas Into Actions
- Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 68 more companies for you to explore.Click here to unveil our expertly curated list of 71 US High Growth Tech and AI Stocks.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Daktronics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com